[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP088176A - Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6 - Google Patents

Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6

Info

Publication number
ECSP088176A
ECSP088176A EC2008008176A ECSP088176A ECSP088176A EC SP088176 A ECSP088176 A EC SP088176A EC 2008008176 A EC2008008176 A EC 2008008176A EC SP088176 A ECSP088176 A EC SP088176A EC SP088176 A ECSP088176 A EC SP088176A
Authority
EC
Ecuador
Prior art keywords
sulfonylindazol
hydroxythyriptamine
azinil
ligands
derivatives
Prior art date
Application number
EC2008008176A
Other languages
English (en)
Inventor
Hassan Mahmoud Elokdah
Albert Jean Robichaud
Alexander Alexei Greenfield
Kevin Liu
Geraldine Ruth Mcfarlane
Cristina Grosanu
Jennifer Rebecca Lo
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088176A publication Critical patent/ECSP088176A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención suministra un compuesto de fórmula I y el uso del mismo para el tratamiento de un desorden del sistema nervioso central relacionado con o afectado por el receptor 5-HT6.
EC2008008176A 2005-08-15 2008-02-12 Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6 ECSP088176A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70831705P 2005-08-15 2005-08-15

Publications (1)

Publication Number Publication Date
ECSP088176A true ECSP088176A (es) 2008-04-28

Family

ID=37315656

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008176A ECSP088176A (es) 2005-08-15 2008-02-12 Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6

Country Status (21)

Country Link
US (1) US7790751B2 (es)
EP (1) EP1915348A1 (es)
JP (1) JP2009504738A (es)
KR (1) KR20080034497A (es)
CN (1) CN101291913A (es)
AR (1) AR056459A1 (es)
AU (1) AU2006291414A1 (es)
BR (1) BRPI0614341A2 (es)
CA (1) CA2619309A1 (es)
CR (1) CR9733A (es)
EC (1) ECSP088176A (es)
GT (1) GT200600374A (es)
IL (1) IL189416A0 (es)
MX (1) MX2008002158A (es)
NO (1) NO20080553L (es)
PE (1) PE20070373A1 (es)
RU (1) RU2008103700A (es)
SV (1) SV2008002653A (es)
TW (1) TW200800913A (es)
WO (1) WO2007032833A1 (es)
ZA (1) ZA200801524B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565872A (en) * 2005-08-15 2011-06-30 Wyeth Corp Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
AU2007274724B2 (en) * 2006-07-14 2012-07-26 Ranbaxy Laboratories Limited Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
ES2358549T3 (es) * 2006-11-09 2011-05-11 F. Hoffmann-La Roche Ag Arilsulfonil, pirrolidinas como inhibidores de 5-ht6.
US7939520B2 (en) 2007-05-15 2011-05-10 Wyeth Llc Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
US20090012308A1 (en) * 2007-06-13 2009-01-08 Wyeth Process for the manufacture of benzylsulfonylarenes
WO2010124042A2 (en) * 2009-04-23 2010-10-28 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135900A0 (en) 1997-11-04 2001-05-20 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeuticaly active compounds
AU5960300A (en) 1999-07-15 2001-02-05 Nps Allelix Corp. Heterocyclic compounds for the treatment of migraine
HUP0400684A2 (hu) * 2000-12-22 2004-07-28 Wyeth 5-Hidroxitriptamin-6-ligandumként használható heterociklilindazol- és -azaindazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
KR20030088508A (ko) 2001-04-20 2003-11-19 와이어쓰 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴옥시-, -티옥시- 및 -아미노벤즈아졸 유도체
BR0209047A (pt) * 2001-04-20 2004-08-10 Wyeth Corp Derivados de heterociclilalcóxi-, -alquiltio- e -alquilaminobenzazol como ligantes de 5-hidroxitriptamina-6
WO2002100833A1 (fr) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Inhibiteurs de rho kinase
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
TW200400177A (en) 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
TW200401641A (en) 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
TW200412945A (en) * 2002-10-25 2004-08-01 Upjohn Co Quaternary ammonium compounds
TW200505904A (en) * 2003-02-14 2005-02-16 Wyeth Corp Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
CN1922150A (zh) 2004-02-27 2007-02-28 霍夫曼-拉罗奇有限公司 吲唑衍生物以及含有它们的药物组合物

Also Published As

Publication number Publication date
PE20070373A1 (es) 2007-04-04
KR20080034497A (ko) 2008-04-21
TW200800913A (en) 2008-01-01
ZA200801524B (en) 2010-04-28
US7790751B2 (en) 2010-09-07
RU2008103700A (ru) 2009-09-27
CA2619309A1 (en) 2007-03-22
JP2009504738A (ja) 2009-02-05
NO20080553L (no) 2008-04-23
MX2008002158A (es) 2008-04-19
SV2008002653A (es) 2008-04-11
WO2007032833A1 (en) 2007-03-22
CR9733A (es) 2008-04-02
AU2006291414A1 (en) 2007-03-22
CN101291913A (zh) 2008-10-22
IL189416A0 (en) 2008-06-05
US20070054896A1 (en) 2007-03-08
EP1915348A1 (en) 2008-04-30
GT200600374A (es) 2007-03-29
AR056459A1 (es) 2007-10-10
BRPI0614341A2 (pt) 2011-03-29

Similar Documents

Publication Publication Date Title
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
PA8795601A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
CO6300955A2 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina -3
CL2007001670A1 (es) Uso de compuestos derivados de amina para el tratamiento de un trastorno mediado por citoquinas.
PA8740901A1 (es) Compuestos organicos
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
GT200600030A (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
CO6640285A2 (es) 5-alquinil-pirimidinas
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk)
PA8790101A1 (es) Derivados de aminoalquilazol como antagonistas de histamina-3
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
ECSP088176A (es) Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
CL2008002767A1 (es) Compuestos derivados de heterociclico triciclico; composicion farmaceutica; y su uso para el tratamiento de un trastorno mediado por serotonina tal como obesidad, esquizofrenia y disfuncion cognitiva.
CO6341625A2 (es) Derivados de indol como agentes anticáncer
PA8781601A1 (es) " derivados de azaciclilbenzamida como antagonistas de histamina-3
ECSP088922A (es) Derivados de amino-tiazol y sus usos como agentes antibacterianos
ECSP088930A (es) Derivados de benzoxazol y benzotiazol como ligandos de
ECSP067096A (es) Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6
ECSP088789A (es) Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6
PA8780701A1 (es) "aminoazaciclil-3-sulfonilindazoles como ligandos de 5-hidroxytryptamine-6"
CU20100045A7 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3